Clinical trials: Primary Open - Angle Glaucoma (POAG)
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension
This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd.
- Trial name
- NCT07661329
- Testing
- Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
- Where
- 22 sites in United States, India
- Volunteers
- 600 people
- Sponsor
- YS Life Science Co., Ltd.
Glaucoma, Open-Angle, Glaucoma, Narrow Angle
Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with…
- Trial name
- SAFARI 3 (NCT05236439)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 57 people
- Sponsor
- Ciliatech
Primary Open Angle Glaucoma
IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy With Collagen Implant
Primary open angle glaucoma (POAG) is associated with inadequate drainage of the aqueous humor via the trabecular meshwork towards the systemic circulation. This may lead to an increase in IOP and may damage the optic nerve.
- Trial name
- NCT01561001
- Testing
- SENSIMED Triggerfish®
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Sensimed AG
Primary Open-angle Glaucoma, Cataract
MINIject Implantation Combined With Cataract Surgery in Patients With POAG and Cataract
The study will assess safety and performance of MINIject implant in patients with open-angle glaucoma uncontrolled by topical hypotensive medications in conjunction with cataract surgery.
- Trial name
- STAR-VI (NCT05432245)
- Testing
- Phacoemulsification combined with minimally invasive glaucoma surgery (MIGS)
- Where
- 4 sites in Panama, Spain and 1 more
- Volunteers
- 30 people
- Sponsor
- iSTAR Medical
Primary Open-angle Glaucoma
Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery
Evaluate the safety and efficacy of the Glaukos Trabecular Micro-Bypass Stent Model GTS400 using the G2-M-IS injector system in conjunction with cataract surgery vs.
- Trial name
- NCT01461291
- Testing
- iStent inject, Cataract surgery
- Where
- United States
- Volunteers
- 505 people
- Sponsor
- Glaukos Corporation
Primary Open-angle Glaucoma and Ocular Hypertension
DE-117 Spectrum 5 Study
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
- Trial name
- NCT03697811
- Testing
- DE-117 Ophthalmic Solution
- Where
- 32 sites in United States
- Volunteers
- 107 people
- Sponsor
- Santen Inc.
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Open-angle Glaucoma
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
- Trial name
- NCT03488550
- Testing
- ANX007
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Annexon, Inc.
Primary Open-Angle Glaucoma, Ocular Hypertension
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
- Trial name
- NCT01915940
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 169 people
- Sponsor
- ForSight Vision5, Inc.
Primary Open Angle Glaucoma
Effect of Xen Implantation on the Aqueous Humor Proteome
The purpose of this study is to determine how the aqueous humor proteome changes after implantation of a Xen microstent for treatment of glaucoma.
- Trial name
- NCT04141865
- Testing
- Xen, Aqueous shunt
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Price Vision Group
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- CONFORTK (NCT03257813)
- Testing
- PRO-122, Krytantek Ofteno®
- Volunteers
- 60 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01518244
- Testing
- Brinzolamide/timolol maleate fixed combination
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma
The Effects of Visior on Ocular Hemodynamics
To determine the relationship between the affects of viewing commercially available content through the VISIOR video goggles and ocular blood flow in glaucoma patients and healthy subjects.
- Trial name
- NCT02959593
- Testing
- VISIOR video goggles
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Visior Technologies Ltd.
Glaucoma
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01336569
- Testing
- Travoprost 0.004%/timolol maleate 0.5% fixed combination
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Glaucoma, Primary Open Angle
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
The objective of this study was to investigate the improving effect of corneal disorder in primary open-angle glaucoma and ocular hypertension patients, when switched from the 0.005% latanoprost ophthalmic solution (one drop at a…
- Trial name
- NCT04737928
- Testing
- Latanoprost, tafluprost
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients.
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
- Trial name
- COMPARE (NCT02023242)
- Testing
- Hydrus Microstent, iStent Trabecular Micro Bypass
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Ivantis, Inc.
Glaucoma, Glaucoma, Open Angle
AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.
- Trial name
- NCT02036541
- Testing
- AqueSys XEN 45 Glaucoma Implant
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- AqueSys, Inc.
Primary Open Angle Glaucoma of Both Eyes
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
The goal of this study is to compare efficacy and safety of Dorzol 20 mg/mL Eye Drops manufactured by JADRAN-GALENSKI LABORATORIJ d.d.
- Trial name
- NCT05973305
- Testing
- Dorzol 20 mg/ml, Trusopt 20 mg/ml
- Where
- Russia
- Volunteers
- 118 people
- Sponsor
- Jadran Galenski laboratorij d.d.
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension
Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH
The primary objective of this study is to evaluate the ocular surface safety of an ophthalmic solution indicated for the management of glaucoma, containing the active ingredients dorzolamide, timolol, and brimonidine, in patients…
- Trial name
- GLAUCO-TECH (NCT07690397)
- Testing
- Preservative-free dorzolamide-timolol-brimonidine combination, Preservative dorzolamide-timolol-brimonidine combination
- Where
- Colombia
- Volunteers
- 140 people
- Sponsor
- Tecnoquimicas